Will Insurance or a Government Scheme — Pay for Pazopanib?

PM-JAY covers families identified as economically vulnerable through the Socio-Economic Caste Census database. The National Health Authority administers it. If your family is on the eligible list, cover extends to cancer treatment packages at empanelled hospitals. Whether pazopanib falls within the package your oncologist uses depends on the specific package code submitted. A social worker at an empanelled centre can check your eligibility instantly using your Aadhaar number and tell you which packages your treatment is likely to fall under.

Both Telangana and Andhra Pradesh run state health schemes that extend cancer coverage beyond PM-JAY for residents who meet the state's eligibility criteria, typically based on ration card category or household income. The AP scheme (YSR Aarogyasri) and the Telangana scheme maintain their own empanelled hospital lists. If you are being treated at a CION centre in either state, ask the social worker whether your centre is empanelled and which cancer packages are available under the relevant state scheme.

CGHS covers serving and retired central government employees and their dependants. Medicines on the CGHS formulary are provided at CGHS dispensaries or reimbursed. If pazopanib is not on the formulary for your indication, your treating oncologist can apply for non-formulary approval through the CGHS Additional Director's office, with a supporting prescription and case summary. Apply at the point of prescription — before you begin paying out of pocket — because the process takes time and reimbursement for past purchases is not guaranteed.

ECHS covers retired armed forces personnel and their dependants. Coverage works similarly to CGHS: medicines on the formulary are provided or reimbursed, and drugs not on the formulary require prior approval from the relevant ECHS polyclinic or regional centre. Bring your discharge book, PPO and a detailed prescription when making the application. Ask the polyclinic exactly which documents are required before your first visit — incomplete paperwork is the most common cause of delay.

ESI covers workers in the organised sector who are registered by their employers and whose earnings fall below the current ESI wage threshold. Cancer treatment, including medicines, is covered for insured persons and their families through ESI hospitals and dispensaries. If ESI does not have a direct facility for your cancer treatment, your oncologist can refer you to a recognised cancer centre and ESI may reimburse the cost. Ask your HR department to confirm that your contributions are current — gaps in contribution can affect your eligibility.

IRDAI guidelines require standard individual health insurance policies not to exclude cancer as a pre-existing condition after the waiting period. However, oral targeted therapies like pazopanib are taken at home and may fall under outpatient cover rather than hospitalisation cover. Many policies limit or exclude outpatient medicines. Ask your insurer in writing whether oral targeted cancer medicines are covered under your specific policy, and keep the written response. Corporate group policies are often more generous — check with your employer's HR before assuming you are not covered.

The manufacturer of branded pazopanib has run patient assistance programmes in India for patients who cannot afford the treatment. Availability and income criteria change, so ask your oncologist or social worker whether a programme is currently active. Separately, generic pazopanib made by Indian manufacturers and approved by CDSCO is available at a significantly lower cost than the branded version. Organisations such as the Indian Cancer Society and CanSupport also provide financial assistance in some cases. Your hospital's oncology social worker is the best starting point for identifying what is available in your city.